Endocrine Abstracts

Despite conventional treatment with oral calcium and active vitamin D, patients with chronic hypoparathyroidism (cHypoPT) can remain not adequately controlled (NAC) and have abnormal biochemistry, disease complications, or symptoms impacting quality of life. A systematic literature review (SLR) was conducted to evaluate the clinical burden for patients with cHypoPT, with an emphasis on patients with NAC disease. This abstract focuses on data related to renal and cardiovascular...

Conventional therapy for chronic hypoparathyroidism is oral calcium and active vitamin D; despite treatment, chronic hypoparathyroidism may be associated with increased risk of renal complications. Without the effect of parathyroid hormone on renal tubular reabsorption, calcium-conserving and phosphaturic effects are lost, serum calcium levels are reduced and serum phosphate levels are increased. This may lead to hypercalciuria and hyperphosphataemia, which may be associated w...

This study investigated risk of cardiovascular (CV) events over a period of up to 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human parathyroid hormone (1–84), rhPTH(1–84), compared with a historical control cohort of patients who did not receive rhPTH(1––84). The rhPTH(1–84)-treated patient cohort was derived from the NCT00732615 (REPLACE), NCT01...

Changes in estimated glomerular filtration rate (eGFR) over 5 years were evaluated in adult patients with chronic hypoparathyroidism. A cohort of patients treated with recombinant human parathyroid hormone (1–84), rhPTH(1–84), was derived from NCT01297309 (RACE) and NCT01199614 (HEXT) clinical trials. A historical control patient cohort with hypoparathyroidism who did not receive rhPTH(1–84) or rhPTH(1&#...

This study evaluated risk of chronic kidney disease (CKD) outcomes over a period of up to 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human parathyroid hormone (1–84), rhPTH(1–84), compared with a historical control cohort of patients who did not receive rhPTH(1–84). The cohort of patients with chronic hypoparathyroidism treated with rhPTH(1–84) was de...

Background: Prior small studies have suggested increased risk of infections in patients with hypoparathyroidism (HypoPT). This study using a large managed care cohort evaluated whether chronic HypoPT is associated with increased risk of sepsis, respiratory infections, and kidney or other genitourinary (GU) infections.Methods: A retrospective cohort study using a US commercial claims database (Q1 2007–Q2 2017) was conducted to examine the association...

Background: Little is known about the risk of developing nephrolithiasis and nephrocalcinosis in patients with chronic HypoPT treated with conventional therapy (ie, oral calcium and active vitamin D). This study evaluated whether HypoPT is associated with increased risk of these conditions.Methods: This retrospective cohort study, based on a large US commercial claims database (Q1 2007–Q2 2017), was conducted to compare the risk of nephrolithiasis a...

Background: Previous studies of smaller size signaled heightened risk of CKD in patients with chronic HypoPT treated with conventional therapy (ie, oral calcium and active vitamin D). However, little is known about CKD progression, including progression to end-stage kidney disease (ESKD), in HypoPT patients.Methods: A retrospective cohort study, using a large US commercial claims database (Q1 2007–Q2 2017), was conducted to compare the risk of CKD b...

Background: Among chronic hypoparathyroidism (HypoPT) patients, the baseline prevalence of type 2 diabetes (T2D) appeared to be higher than the general population in previous studies. Since little is known about the potential assocation between HypoPT and T2D, this study evaluated whether HypoPT is associated with increased risk of T2D.Methods: A retrospective cohort study, based on a US commercial claims database (Q1 2007 – Q2 2017), was conducted ...

Background: Prior small studies have suggested increased risk of cardiovascular (CV) conditions in patients with hypoparathyroidism (HypoPT). We evaluated whether chronic HypoPT is associated with increased risk of select CV hard endpoints (i.e., myocardial infarction (MI), stroke, and a composite CV endpoint) in a large contemporary cohort.Methods: A retrospective cohort study, based on a US commercial claims database (Q1 2007 - Q2 2017), was conducted ...